Swedish biotechnology company Probi has announced the signing of a distribution and supply agreement with Sanofi.
Subscribe to our email newsletter
Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestisstarting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters.
Sanofi is a leading Healthcare company with more than 100.000 employees worldwide and plays an important role in the global probiotic consumer market. Sanofi’s Consumer Healthcare division in Korea offers diverse vitamins, minerals, and health supplements under the well-established Cenovis brand. Sanofi Korea is one of the major players in dietary supplements in the mass retail channel in Korea.
Sanofi Korea Consumer Healthcare head DongWoo Shin noted that Probiotics is the next major growth category in Korea and the launch of Probi Digestis will be its focus for the Cenovis brand in 2014 and 2015.
"In Probi Digestis we found a high quality probiotic product with good clinical documentation and we plan to extend the Probi range further, so it will play an important role in the Cenovis probiotic strategy going forward," Shin added.
Probi Digestis will be launched in all channels Sanofi Korea is currently operating in, mass retail, department stores, drugstore/pharmacy, internet and TV home shopping. The product will be sold with Probi Digestis predominantly displayed on front of the pack and Sanofi will make substantial consumer marketing investment during the launch.
Probi Digestis is based on Lactobacillus plantarum 299v (DSM 9843), which targets bloating, gas formation and pain, common symptoms that are sometimes mild or temporary but often more severe and diagnosed as IBS – Irritable Bowel Syndrome.